GlassScriptPhysician profile
Joseph Attallah
NPI 1700266129
$2,266.21
in general payments reported to CMS, 2019-2025
23 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $39.00 · 2021: $81.95 · 2022: $598 · 2023: $428 · 2024: $659 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.88 |
| Education | $273.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $557.43 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $473.81 | 2020-2025 | Calquence, Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $140.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.67 | 2025 | |
| Genentech USA, INC. | $124.80 | 2024 | Columvi, Lunsumio |
| Eisai INC. | $103.28 | 2024 | |
| Exelixis INC. | $103.01 | 2023-2024 | |
| Abbvie INC. | $82.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Lifenet Health | $55.56 | 2025 | Pliafx Flo, Allograft Vmis Delivery System |
| Beigene USA, INC. | $51.77 | 2022-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $39.48 | 2019 | |
| Genzyme Corporation | $38.91 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $37.05 | 2019-2020 | |
| Pfizer INC. | $36.59 | 2019-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.47 | 2024 | Onivyde |
| Blueprint Medicines Corporation | $31.87 | 2023 | Ayvakit |
| Janssen Biotech, INC. | $31.81 | 2023 | Carvykti, Darzalex, Tecvayli |
| Tempus Ai, INC | $29.55 | 2025 | Xt Cdx |
| Taiho Oncology, INC. | $23.53 | 2021 | |
| Iovance Biotherapeutics, INC. | $21.17 | 2025 | Amtagvi |
| Merck Sharp & Dohme LLC | $17.84 | 2019 | |
| Amgen INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Attallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.